Neoadjuvant chemotherapy in colon cancer: what the ELECLA trial shows
The Spanish ELECLA trial, published in ESMO Open with the participation of Dr. Patricia Tejedor, evaluates giving chemotherapy before surgery in locally advanced colon cancer with a proficient mismatch repair (pMMR) molecular profile.
The ELECLA trial (ESMO Open, 2026), with the participation of Dr. Patricia Tejedor, shows that neoadjuvant chemotherapy in pMMR locally advanced colon cancer is safe and feasible, reduces tumor volume and improves pathologic features, without increasing surgical complications.
References
Published in: ESMO Open (2026)
DOI: 10.1016/j.esmoop.2026.108250